The mechanism of action:
Tadalista is a drug that contains tadalafil. The active component of the selectively reversible drug inhibits cyclic guanosine monophosphate (cGMP) - specific phosphodiesterase type 5 (PDE 5). During sexual stimulation the local release of nitric oxide is marked, while the specific inhibition of phosphodiesterase activity of type 5 leads to an increase in the level of cGMP in cavernous bodies. Under the effect of tadalafil there is a decrease in smooth muscle tone and increased blood flow to the penile tissues, which contributes to an improvement in erection. Tadalafil has no sexual stimulation.
The action of tadalafil on other phosphodiesterases is light, therefore Tadalista has no effect on the cardiovascular system, on the function of the liver, skeletal muscle and other organs. Tadalafil does not change the quality characteristics of sperm, it does not cause changes in the level of testosterone, follicle stimulating hormone and luteinizing hormone in the blood.
The effect of the Tadalista drug develops only on condition of sexual stimulation. The beginning of the therapeutic effect of tadalafil occurs 15 minutes after administration. Tadalista works within 36 hours after oral administration.
The active component of the drug Tadalista is well absorbed after oral administration. The maximum plasma concentration of tadalafil is reached within 2 hours after ingestion. The bioavailability and absorption rate of tadalafil is independent of food intake. Approximately 94% of tadalafil is bound to plasma proteins. The active component of Tadalista is metabolized, with the participation of the enzyme CYP3 A4. Tadalafil is eliminated mainly as metabolites from the kidneys and intestines, the half-life reaches 17.5 hours.
Directions for use:
Tadalista is used to treat patients with erectile dysfunction.
How to use:
Tadalista is intended for oral administration. Film-coated tablets, it is recommended to take the whole, drinking plenty of drinking water or tea. Tadalista is taken with or without food. The dosage regimen of Tadalista is established by the doctor.
Generally it is prescribed to take 1 tablet, coated with film, 15-20 minutes before anticipating sexual activity. Considering that the effect persists after a single dose up to 36 hours, a tablet can be taken earlier.
The maximum recommended daily dose of Tadalista is 1 tablet.
Patients may develop headaches and dyspeptic phenomena when taking the drug Tadalista. In addition, some cases of back pain development, facial redness, nasal obstruction, myalgia, eye pain, conjunctival hyperaemia, dizziness and angioedema while taking tadalafil have been reported.
There are data on the development of priapism and prolonged erection while taking Tadalista. If an erection persists for more than 4 hours, consult a doctor as long-term storage of an erection can damage penile tissue loss and long-term potency.
- Tadalista is not indicated for patients with known hypersensitivity to tadalafil.
- Admission of Tadalista is contraindicated to patients taking organic nitrates.
- Tadalafil is not indicated for women and children under the age of 18.
It is not recommended to take the drug Tadalista to patients with diseases of the cardiovascular system, in which sexual activity is not desirable, including patients with recent myocardial infarction or a stroke, as well as suffering from second-degree heart failure, unstable angina, arrhythmia or uncontrolled hypertension, expressed by arterial hypotension.
Patients with an increased risk of developing risk of priapism should be used with caution, including patients with leukemia, serpopodobno-cell anemia, multiple myeloma, angular curvature of the penis, cavernous fibrosis and Peyronie's disease .
In addition, the appointment of tadalafil should be used with caution for patients suffering from renal and hepatic function, and for patients who are treated with alpha-blockers.
Interactions with other drugs:
The simultaneous use of organic nitrates with tadalafil is prohibited.
Tadalafil does not change the pharmacokinetic profile of drugs, metabolised with the participation of cytochrome P450.
Increased plasma concentrations of tadalafil are possible in combination with admission of the Tadalista drug and CYP3 A4 inhibitors.
In particular, tadalafil should be used with caution in combination with ketakonazolom, ritonavir, saquinavir, erythromycin and itraconazole.
Perhaps the decrease in plasma concentrations of tadalafil in combination...